Bio-Techne (TECH) Stock Price, News & Analysis

+0.89 (+1.42%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.22 million shs
Average Volume
1.07 million shs
Market Capitalization
$10.01 billion
P/E Ratio
Dividend Yield
Price Target

Bio-Techne MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
31.7% Upside
$83.90 Price Target
Short Interest
3.38% of Shares Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.83mentions of Bio-Techne in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$800,592 Sold Last Quarter
Proj. Earnings Growth
From $1.52 to $1.81 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.98 out of 5 stars

Medical Sector

7th out of 910 stocks

Biotechnology Industry

1st out of 13 stocks

TECH stock logo

About Bio-Techne Stock (NASDAQ:TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Stock Price History

TECH Stock News Headlines

Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Navigating 4 Analyst Ratings For Bio-Techne
Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
TECH Bio-Techne Corporation
7 Biotech Stocks Ready to Ride the Sector's Resurgence
TECH Apr 2024 65.000 call
TECH Apr 2024 60.000 put
Wall Street Lunch: Tick Tock On TikTok
See More Headlines
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 2/26 Dividend
Dividend Payable
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Life Sciences Tools & Services
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
$285.26 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$2.59 per share
Book Value
$12.49 per share


Free Float
Market Cap
$10.06 billion

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

TECH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TECH shares.
View TECH analyst ratings
or view top-rated stocks.

What is Bio-Techne's stock price target for 2024?

10 analysts have issued 12 month price objectives for Bio-Techne's shares. Their TECH share price targets range from $65.00 to $120.00. On average, they expect the company's share price to reach $83.90 in the next year. This suggests a possible upside of 31.7% from the stock's current price.
View analysts price targets for TECH
or view top-rated stocks among Wall Street analysts.

How have TECH shares performed in 2024?

Bio-Techne's stock was trading at $77.16 at the beginning of 2024. Since then, TECH stock has decreased by 17.5% and is now trading at $63.69.
View the best growth stocks for 2024 here

When is Bio-Techne's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our TECH earnings forecast

How can I listen to Bio-Techne's earnings call?

Bio-Techne will be holding an earnings conference call on Wednesday, May 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13745802".

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) issued its quarterly earnings data on Thursday, February, 1st. The biotechnology company reported $0.33 earnings per share for the quarter, missing the consensus estimate of $0.36 by $0.03. The biotechnology company earned $272.60 million during the quarter, compared to analysts' expectations of $277.48 million. Bio-Techne had a trailing twelve-month return on equity of 14.21% and a net margin of 19.58%.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Thursday, February 1st. Stockholders of record on Monday, February 12th will be paid a dividend of $0.08 per share on Monday, February 26th. This represents a $0.32 annualized dividend and a dividend yield of 0.50%. The ex-dividend date is Friday, February 9th.
Read our dividend analysis for TECH

Is Bio-Techne a good dividend stock?

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.52%. The dividend payout ratio is 23.19%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 17.68% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

When did Bio-Techne's stock split?

Bio-Techne's stock split on the morning of Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly minted shares were issued to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Charles Kummeth has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a number of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.91%), Allspring Global Investments Holdings LLC (0.82%), Raymond James & Associates (0.21%), Rowlandmiller & PARTNERS.ADV (0.03%), Azzad Asset Management Inc. ADV (0.03%) and State of Michigan Retirement System (0.03%). Insiders that own company stock include Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Bio-Techne have any subsidiaries?
The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More
This page (NASDAQ:TECH) was last updated on 4/23/2024 by Staff

From Our Partners